Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

CardioNet, Inc. and AirStrip Partner to Expand Mobile Patient Monitoring

CardioNet Inc.
Posted on: 13 Feb 13

As health systems are under increasing pressure to share data across systems to improve and expand their networks of care, CardioNet, Inc. and AirStrip have entered into a partnership agreement to develop and co-market an integrated solution for mobile patient monitoring.

The AirStripTM mobility solution will deliver live patient data from CardioNet’s Mobile Cardiac Outpatient TelemetryTM (MCOTTM) directly to clinicians’ mobile devices, including tablets and phones. This integrated solution will enable health systems to combine critical cardiac data with EMR and device information to improve patient monitoring and clinician decision-making at the point of care.

“This partnership is the foundation for a powerful end-to-end cardiac care package that promises to have a game-changing impact on 30-day readmissions for heart failure,” said Alan Portela, AirStrip CEO. “Our pioneering mobility solution delivers critical patient data to physicians anywhere across the care continuum to encourage better decision-making and improve both the timeliness and quality of care. This integration with CardioNet’s platform enables health systems to empower clinicians with the information they need to achieve key quality metrics in cardiology – one of the most resource and time-intensive practice areas within healthcare.”

While details of the partnership agreement were not disclosed, it is exclusive to select markets. The two companies expect to deliver a market-ready solution by mid-year.

Joseph H. Capper, CardioNet’s President and CEO, commented: “This collaboration is one of the most exciting initiatives CardioNet has embarked on to date. As the leader in the mobile cardiac telemetry market, we are always looking for avenues to expand the utilization of our data. The AirStrip solution is the leading FDA-cleared technology for the transmission of virtual, live ECG waveforms to a healthcare provider’s mobile device. This solution is rapidly transforming the way clinical data is delivered and integrated in a point of care setting. Incorporating the timely, accurate information derived from MCOTTM into AirStrip’s state-of-the-art mobile system will undoubtedly improve the physician’s ability to deliver the proper treatment, the first time.”

Tweet This: @AirStripmHealth and @CardioNetMCOT partner to enable mobile patient monitoring in cardiac care

About CardioNet, Inc.

CardioNet is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual’s health. CardioNet’s initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient Telemetry™ (MCOT™). Through its Cardiocore division, CardioNet is offers core lab services to pharmaceutical and devise sponsors as they mover new products through the development process. More information can be found at http://www.cardionet.com.

About AirStrip

AirStrip (www.airstriptech.com) provides healthcare’s only complete, vendor- and data source-agnostic enterprise-wide clinical mobility solution, which enables clinicians to improve the health of individuals and populations. With deep clinical expertise and strong roots in mobile technology and data integration, AirStrip is empowering the nation’s leading health systems as the industry continues to evolve to new business models, accountable care and shared risk. Based in San Antonio, Texas, AirStrip allows health systems to unlock the full potential of their existing technology investments with a complete mobility solution that provides access to critical patient data across the care continuum. AirStrip is backed by investments from Sequoia Capital, Qualcomm, Inc., Hospital Corporation of America (HCA) and the Wellcome Trust.

Follow AirStrip

CARDIONET CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in the Company’s future. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, the effect of the Cardiocore acquisition on our business operations and financial results and our ability to successfully integrate its operations into our business, the national rate set by the Centers for Medicare and Medicaid Services (“CMS”) for our mobile cardiovascular telemetry service, effects of changes in health care legislation, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, our ability to develop and co-market an integrated telemetry platform with Airstrip Technologies, Inc., the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, and litigation success. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Business Wire
http://www.businesswire.com/

Last updated on: 13/02/2013

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.